Duopharma Biotech Berhad is partnering with RenalWorks Malaysia Sdn Bhd, a subsidiary of Singapore-based RenalWorks Pte Ltd to enhance dialysis services through the provision of the proprietary RenalGenie Electronic Health Record (EHR) dialysis software.
The software was formally introduced to healthcare providers following the recent signing of an agreement between Duopharma (M) Sdn Bhd, a subsidiary of Duopharma Biotech, and RenalWorks Malaysia Sdn Bhd, whereby Duopharma Biotech will be the exclusive sales and marketing partner for RenalGenie EHR dialysis software in Malaysia, with potential expansion to other ASEAN markets in the future.
Innovated with the needs of independent, group and hospital-based dialysis facilities of all sizes in mind, the highly-scalable and adaptable RenalGenie EHR dialysis software focuses on streamlining data flows, and strengthening patient care and compliance, while ensuring that healthcare facilities can provide the highest standards of service with optimised operational efficiency.
The all-in-one healthcare facilities management software taps on the latest cloud-based accessibility and mobile technologies to enable remote management and overcome the challenges of installing conventional dialysis EHR systems.
Via a comprehensive and centralised database recording up-to-date patient health data, healthcare providers are empowered with informed decision-making, with optimised healthcare facilities management and care coordination and a user-friendly interface.
The RenalGenie EHR dialysis software also conforms to international standards for quality, safety, security and privacy, and is certified under ISO 9001:2015 Quality Management System for design, development, manufacture, distribution and service of administrative, financial and management support for clinical software.
The software is also in accordance with the USA’s Health Insurance Portability and Accountability Act (HIPAA) and the European Union’s General Data Protection Regulation (GDPR) requirements.
“As a Malaysian healthcare company with a vision of ‘Providing Smarter Solutions for a Healthier Life’, Duopharma Biotech is always on the lookout for potential partners with innovations to support better healthcare outcomes.
“While it is crucial for the Ministry of Health and other stakeholders to work on preventing disease, it is also critical to take a long-term view on improving healthcare outcomes by improving treatment for existing patients. In terms of dialysis, Malaysia is unfortunately looking at an uptick in kidney disease and kidney failure patients in the years to come, so it is important to lay the groundwork now for healthcare systems to support this future need.
“In addition, implementation of the RenalGenie EHR dialysis software is also in line with national efforts to expand digitalisation for improving healthcare service delivery, and in turn, elevate outcomes,” said Leonard Ariff Abdul Shatar, Group Managing Director, Duopharma Biotech Berhad.
Malaysia is projected to have as many as 106,000 kidney failure patients by 2040, of which 30% will be aged under 45, impacted by a dramatic rise in the prevalence of chronic kidney disease, from 9.07% in 2011 to 15.48% in 2018.
Approximately one in seven Malaysians suffer from chronic kidney disease, comprising 4.7 million adults, with more than 9,000 new dialysis patients identified every year. Meanwhile, the Ministry of Health has identified digitalisation as a priority in healthcare ecosystem reform to improve delivery of healthcare services, focusing on factors such as better care coordination and continuity of care, and the transformation of all healthcare facilities into modern, efficient and patient-centred facilities.
Elaborating on the development of the RenalGenie EHR dialysis software, Chan Wai Chuen, founder and managing director of RenalWorks Pte Ltd, said, “We innovated RenalGenie to achieve new standards in patient care, safety and outcomes with comprehensive treatment functionalities to address key pain points and data gaps in dialysis care.
“With RenalGenie, healthcare facilities can substantially reduce operational costs by streamlining workflow processes and improve revenue by applying our proprietary automated billing algorithms and scheduler to optimise healthcare facilities’ capacity utilisation.
“Indeed, our survey at the Malaysian Society of Nephrology’s conference in July 2023 found that 44% of respondents rely solely on paper-based processes in their healthcare facilities, whilst 37% rely on a combination of paper-based and software processes. This indicates a high level of unmet demand for dialysis-focused EHR software to enhance clinical, billing and workflow processes.”
Chan said the RenalGenie EHR “marks a significant milestone in RenalWorks’ mission to democratise dialysis EHR software to overcome the technological divide between dialysis centres in developed and middle-income countries.
This goal is realised by eliminating expenses related to software licenses, hardware procurement, installations and complex integrations typical of current EHR software. By leveraging advancements in cloud computing, the widespread use of the web, and the adoption of mobile devices, RenalGenie offers an affordable, accessible, and easily adoptable EHR solution, particularly for middle-income markets.
RenalGenie distinguishes itself with its capability for remote setup in any healthcare facilities, regardless of its location or size, within a week. This allows healthcare facilities to quickly realise value from efficient patient and healthcare facilities management, and administrative tasks.
Its integrated patient database empowers doctors to remotely monitor and manage patients and aids clinical teams in collaborating and making informed, timely decisions. This functionality is crucial in improving patient outcomes and minimising the costs and risks associated with misdiagnosis or delayed treatment.”
For more information on the RenalGenie EHR dialysis software, please visit https://renalworks.com/.
***
ABOUT DUOPHARMA BIOTECH BERHAD
Duopharma Biotech Group (“Duopharma Biotech” or “the Company”) began with the establishment of Duopharma (M) Sendirian Berhad in 1978. Duopharma Biotech was incorporated in 2000 and is today one of Malaysia’s leading pharmaceutical companies listed on the Main Market of Bursa Malaysia Berhad.
Duopharma Biotech has core competencies in the pharmaceutical industry inclusive of Manufacturing, Research & Development and Commercialisation & Marketing of over 300 generic drugs such as Crystorvas, Prelica and Omesec as well as Consumer Healthcare (“CHC”) products including CHAMPS®, FLAVETTES®, PROVITON® and Uphamol, which are well-recognised and accepted by consumers in Malaysia, regionally and globally. The Company has also diversified into the biosimilars space with technology and commercialisation collaborations with credible and strong international partners. ERYSAA®, Basalog One®, and Zuhera are a few commercialised biosimilar brands.
Headquartered in Kuala Lumpur, Malaysia, Duopharma Biotech owns and operates three manufacturing plants in Klang, Bangi and Glenmarie, Selangor. Duopharma Biotech also has subsidiary companies in Indonesia, the Philippines and Singapore. A subsidiary of Duopharma Biotech Berhad has a representative office in Jakarta, Indonesia.
